How I treat priapism

Blood

Volumn 125, Issue 23, 2015, Pages 3551-3558

  Anele, Uzoma A ^a   Le, Brian V ^a   Resar, Linda M S ^a   Burnett, Arthur L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTIANDROGEN; ANTIINFECTIVE AGENT; HEMOGLOBIN; HYDROXYUREA; MORPHINE; NITRIC OXIDE; OPIATE; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR;

ANALGESIA; ANDROGEN THERAPY; ANTIBIOTIC THERAPY; ARTICLE; BLOOD GAS ANALYSIS; CAVERNOSAL TISSUE ISCHEMIA; DIAGNOSTIC IMAGING; DOPPLER ECHOGRAPHY; EMERGENCY WARD; ERECTILE DYSFUNCTION; EXERCISE; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HUMAN; ISCHEMIA; ISCHEMIC PRIAPISM; LABORATORY TEST; MEDICAL HISTORY; NONISCHEMIC PRIAPISM; PAIN; PAINFUL ERECTION; PATHOPHYSIOLOGY; PATIENT MONITORING; PENILE BLOOD FLOW; PHYSICAL EXAMINATION; PHYSIOLOGY; PRACTICE GUIDELINE; PRIAPISM; PRIORITY JOURNAL; RECURRENT ISCHEMIC PRIAPISM; SELF INJECTION; SICKLE CELL ANEMIA; TISSUE INJURY; ANEMIA, SICKLE CELL; COMPLICATION; MALE; PENIS; VASCULARIZATION;

ANEMIA, SICKLE CELL; HUMANS; ISCHEMIA; MALE; PENIS; PRIAPISM;

EID: 84930958693     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-551887     Document Type: Article

References (111)

1. Berger R, Billups K, Brock G, et al AFUD Thought Leader Panel on Evaluation and Treatment of Priapism. Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. Int J Impot Res. 2001;13(suppl 5):S39-S43.
2. Montague DK, Jarow J, Broderick GA, et al Members of the Erectile Dysfunction Guideline Update Panel; Americal Urological Association. American Urological Association guideline on the management of priapism. J Urol. 2003;170(4 pt 1):1318-1324.
3. Morrison BF, Burnett AL. Priapism in hematological and coagulative disorders: an update. Nat Rev Urol. 2011;8(4):223-230.
4. Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin North Am. 2007;34(4):631-642, viii.
5. Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. 2001;57(5):970-972.
6. Adeyoju AB, Olujohungbe AB, Morris J, et al. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int. 2002;90(9):898-902.
7. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. 1980;140(11):1434-1437.
8. Nelson JH III, Winter CC. Priapism: evolution of management in 48 patients in a 22-year series. J Urol. 1977;117(4):455-458.
9. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21(6):518-522.
10. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53(3):417-450.
11. Olujohungbe A, Burnett AL. How I manage priapism due to sickle cell disease. Br J Haematol. 2013;160(6):754-765.
12. Christ GJ, Richards S, Winkler A. Integrative erectile biology: the role of signal transduction and cell-to-cell communication in coordinating corporal smooth muscle tone and penile erection. Int J Impot Res. 1997;9(2):69-84.
13. Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL. New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med. 2012;9(1):79-87.
14. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75(1):191-236.
15. Fournier GR Jr, Juenemann KP, Lue TF, Tanagho EA. Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration. J Urol. 1987;137(1):163-167.
16. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science. 1992;257(5068):401-403.
17. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326(2):90-94.
18. Ignarro LJ. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol. 1990;67(1):1-7.
19. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999;274(20):13729-13732.
20. Broderick GA. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. J Sex Med. 2012;9(1):88-103.
21. Song PH, Moon KH. Priapism: current updates in clinical management. Korean J Urol. 2013;54(12):816-823.
22. Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol. 1986;135(1):142-147.
23. Ralph DJ, Garaffa G, Muneer A, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009;56(6):1033-1038.
24. Kovac JR, Mak SK, Garcia MM, Lue TF. A pathophysiology-based approach to the management of early priapism. Asian J Androl. 2013;15(1):20-26.
25. Addis G, Spector R, Shaw E, Musumadi L, Dhanda C. The physical, social and psychological impact of priapism on adult males with sickle cell disorder. Chronic Illn. 2007;3(2):145-154.
26. Burnett AL, Bivalacqua TJ. Glucose-6-phosphate dehydrogenase deficiency: an etiology for idiopathic priapism? J Sex Med. 2008;5(1):237-240.
27. Prabhakaran K, Jacobs BL, Smaldone MC, Franks ME. Stuttering priapism associated with hereditary spherocytosis. Can J Urol. 2007;14(5):3702-3704.
28. Kato GJ. Priapism in sickle-cell disease: a hematologist's perspective. J Sex Med. 2012;9(1):70-78.
29. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005;106(9):3264-3267.
30. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-2285.
31. Elliott L, Ashley-Koch AE, De Castro L, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol. 2007;137(3):262-267.
32. Nolan VG, Baldwin C, Ma Q, et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol. 2005;128(2):266-272.
33. Anele UA, Burnett AL. Erectile dysfunction after sickle cell disease-associated recurrent ischemic priapism: profile and risk factors. J Sex Med. 2015;12(3):713-719.
34. Burnett AL, Bivalacqua TJ. Priapism: new concepts in medical and surgical management. Urol Clin North Am. 2011;38(2):185-194.
35. Yuan J, Desouza R, Westney OL, Wang R. Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl. 2008;10(1):88-101.
36. Ramos CE, Park JS, Ritchey ML, Benson GS. High flow priapism associated with sickle cell disease. J Urol. 1995;153(5):1619-1621.
37. Melman A, Serels S. Priapism. Int J Impot Res. 2000;12(suppl 4):S133-S139.
38. Hinman F Jr. Priapism; reasons for failure of therapy. J Urol. 1960;83:420-428.
39. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci USA. 2005;102(5):1661-1666.
40. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL. Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol. 2007;51(6):1732-1740.
41. Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL, Champion HC. Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med. 2009;6(9):2494-2504.
42. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009;84(9):618-625.
43. Houston M, Estevez A, Chumley P, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. 1999;274(8):4985-4994.
44. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA. 2001;98(26):15215-15220.
45. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol. 2007;34(9):926-932.
46. Bivalacqua TJ, Ross AE, Strong TD, et al. Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell mice. Urology. 2010;76(2):510.e7-e12.
47. Kanika ND, Tar M, Tong Y, Kuppam DS, Melman A, Davies KP. The mechanism of opiorphin-induced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol. 2009;297(4):C916-C927.
48. Mi T, Abbasi S, Zhang H, et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest. 2008;118(4):1491-1501.
49. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med. 2008;5(5):1244-1250.
50. LeRoy TJ, Broderick GA. Doppler blood flow analysis of erectile function: who, when, and how. Urol Clin North Am. 2011;38(2):147-154.
51. Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127(7):664-668.
52. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3(6):1077-1084.
53. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67(5):1043-1048.
54. Machado RF, Barst RJ, Yovetich NA, et al; walk-PHaSST Investigators and Patients. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118(4):855-864.
55. Olujohungbe AB, Adeyoju A, Yardumian A, et al. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial - the priapism in sickle cell study. J Androl. 2011;32(4):375-382.
56. Abern MR, Levine LA. Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol. 2009;182(4):1401-1406.
57. Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology. 2002; 59(1):138.
58. Serjeant GR, de Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sickle-cell disease. Lancet. 1985;2(8467):1274-1276.
59. Shamloul R, el Nashaar A. Idiopathic stuttering priapism treated successfully with low-dose ethinyl estradiol: a single case report. J Sex Med. 2005;2(5):732-734.
60. Steinberg J, Eyre RC. Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol. 1995;153(1):152-153.
61. Hoeh MP, Levine LA. Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes. J Sex Med. 2014;11(1):197-204.
62. Yamashita N, Hisasue S, Kato R, et al. Idiopathic stuttering priapism: recovery of detumescence mechanism with temporal use of antiandrogen. Urology. 2004;63(6):1182-1184.
63. Morrison BF, Burnett AL. Stuttering priapism: insights into pathogenesis and management. Curr Urol Rep. 2012;13(4):268-276.
64. Goetz T, Burnett AL. Prostate cancer risk after anti-androgen treatment for priapism. Int Urol Nephrol. 2014;46(4):757-760.
65. Anele UA, Morrison BF, Burnett AL. Molecular pathophysiology of priapism: emerging targets. [published online ahead of print November 10, 2014]. Curr Drug Targets. 2014.
66. Morrison BF, Reid M, Madden W, Burnett AL. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Andrology. 2013;1(4):576-582.
67. Burnett AL, Kan-Dobrosky N, Miller MG. Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. J Sex Med. 2013;10(4):1151-1161.
68. Morrison BF, Anele UA, Reid ME, Madden WA, Feng Z, Burnett AL. Is testosterone deficiency a possible risk factor for priapism associated with sickle-cell disease? Int Urol Nephrol. 2015;47(1):47-52.
69. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med. 2005;2(6):759-770.
70. Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145(5):2253-2263.
71. Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res. 1995;7(4):209-219.
72. Al Jam'a AH, Al Dabbous IA. Hydroxyurea in the treatment of sickle cell associated priapism. J Urol. 1998;159(5):1642.
73. Saad ST, Lajolo C, Gilli S, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77(1):45-49.
74. Anele UA, Kyle Mack A, Resar LM, Burnett AL. Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature. Int Urol Nephrol. 2014;46(9):1733-1736.
75. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood. 2006;108(1):184-191.
76. Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002;116(2):436-444.
77. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300-5311.
78. Danielson CF. The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease. Ther Apher. 2002;6(1):24-31.
79. Swerdlow PS. Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006;2006(1):48-53.
80. Merritt AL, Haiman C, Henderson SO. Myth: blood transfusion is effective for sickle cell anemia-associated priapism. C JEM. 2006;8(2):119-122.
81. Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol. 1993;150(5 pt 1):1480-1482.
82. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048.
83. Chung SY, Stein RJ, Cannon TW, Nelson JB. Novel technique in the management of low flow priapism. J Urol. 2003;170(5):1952.
84. Burnett AL, Sharlip ID. Standard operating procedures for priapism. J Sex Med. 2013;10(1):180-194.
85. Salonia A, Eardley I, Giuliano F, et al European Association of Urology. European Association of Urology guidelines on priapism. Eur Urol. 2014;65(2):480-489.
86. Bodner DR, Lindan R, Leffler E, Kursh ED, Resnick MI. The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury. J Urol. 1987;138(2):310-311.
87. Lee M, Cannon B, Sharifi R. Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism. J Urol. 1995;153(4):1182-1183.
88. Muneer A, Minhas S, Freeman A, Kumar P, Ralph DJ. Investigating the effects of high-dose phenylephrine in the management of prolonged ischaemic priapism. J Sex Med. 2008;5(9):2152-2159.
89. Munarriz R, Wen CC, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside. J Sex Med. 2006;3(5):918-922.
90. Zacharakis E, Raheem AA, Freeman A, et al. The efficacy of the T-shunt procedure and intracavernous tunneling (snake maneuver) for refractory ischemic priapism. J Urol. 2014;191(1):164-168.
91. Burnett AL, Pierorazio PM. Corporal "snake"maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med. 2009;6(4):1171-1176.
92. Segal RL, Readal N, Pierorazio PM, Burnett AL, Bivalacqua TJ. Corporal Burnett "Snake" surgical maneuver for the treatment of ischemic priapism: long-term followup. J Urol. 2013;189(3):1025-1029.
93. Winter CC. Cure of idiopathic priapism: new procedure for creating fistula between glans penis and corpora cavernosa. Urology. 1976;8(4):389-391.
94. Ebbehoj J. A new operation for priapism. Scand J Plast Reconstr Surg. 1974;8(3):241-242.
95. Lue TF, Pescatori ES. Distal cavernosum-glans shunts for ischemic priapism. J Sex Med. 2006;3(4):749-752.
96. Brant WO, Garcia MM, Bella AJ, Chi T, Lue TF. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol. 2009;181(4):1699-1705.
97. Quackels R. Treatment of a case of priapism by cavernospongious anastomosis . Acta Urol Belg. 1964;32:5-13.
98. Sacher EC, Sayegh E, Frensilli F, Crum P, Akers R. Cavernospongiosum shunt in the treatment of priapism. J Urol. 1972;108(1):97-100.
99. Resnick MI, Holland JM, King LR, Grayhack JT. Priapism in boys. Management with cavernosaphenous shunt. Urology. 1975;5(4):492-495.
100. Burnett AL. Surgical management of ischemic priapism. J Sex Med. 2012;9(1):114-120.
101. Rodríguez J, Cuadrado JM, Frances A, Franco E. High-flow priapism as a complication of a venoocclusive priapism: two case reports. Int J Impot Res. 2006;18(2):215-217.
102. Bertolotto M, Ciampalini S, Martingano P, Mucelli FP. High-flow priapism complicating ischemic priapism following iatrogenic laceration of the dorsal artery during a Winter procedure. J Clin Ultrasound. 2009;37(1):61-64.
103. Levey HR, Segal RL, Bivalacqua TJ. Management of priapism: an update for clinicians. Ther Adv Urol. 2014;6(6):230-244.
104. Donaldson JF, Rees RW, Steinbrecher HA. Priapism in children: a comprehensive review and clinical guideline. J Pediatr Urol. 2014;10(1):11-24.
105. Fu S, Tar MT, Melman A, Davies KP. Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells. FASEB J. 2014;28(8):3633-3644.
106. Kanika ND, Melman A, Davies KP. Experimental priapism is associated with increased oxidative stress and activation of protein degradation pathways in corporal tissue. Int J Impot Res. 2010;22(6):363-373.
107. Bivalacqua TJ, Musicki B, Hsu LL, Berkowitz DE, Champion HC, Burnett AL. Sildenafil citrate-restored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress. PLoS ONE. 2013;8(7):e68028.
108. Lagoda G, Sezen SF, Hurt KJ, Cabrini MR, Mohanty DK, Burnett AL. Sustained nitric oxide (NO)-releasing compound reverses dysregulated NO signal transduction in priapism. FASEB J. 2014;28(1):76-84.
109. Wen J, Jiang X, Dai Y, et al. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med. 2010;7(9):3011-3022.
110. Ning C, Wen J, Zhang Y, et al. Excess adenosine A2B receptor signaling contributes to priapism through HIF-1α mediated reduction of PDE5 gene expression. FASEB J. 2014;28(6):2725-2735.
111. Burnett AL. Sexual health outcomes improvement in sickle cell disease: a matter of health policy? J Sex Med. 2012;9(1):104-113.